Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E7820 + irinotecan
- Development stage
- Discontinued
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves E7820, an oral antiangiogenic sulfonamide that inhibits alpha-2 integrin expression, and irinotecan, a semisynthetic derivative of camptothecin used in cancer treatment. E7820 is being investigated for its potential in treating various cancers, while irinotecan is commonly used for metastatic colorectal cancer.
02
Targets
ITGA2 (Integrin alpha-2)RBM39 (RNA-binding motif protein 39)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on E7820 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E7820 + irinotecan.